Stifel Financial Corp Has $5.80 Million Stake in argenx SE (NASDAQ:ARGX)

Stifel Financial Corp increased its stake in shares of argenx SE (NASDAQ:ARGX) by 6.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,433 shares of the company’s stock after purchasing an additional 601 shares during the quarter. Stifel Financial Corp’s holdings in argenx were worth $5,801,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ARGX. GeoWealth Management LLC lifted its position in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after buying an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in shares of argenx in the fourth quarter worth $37,000. Global Retirement Partners LLC raised its holdings in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after acquiring an additional 48 shares in the last quarter. FIL Ltd acquired a new stake in argenx during the fourth quarter valued at $38,000. Finally, Jones Financial Companies Lllp grew its stake in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

NASDAQ:ARGX opened at $629.51 on Wednesday. argenx SE has a one year low of $352.77 and a one year high of $678.21. The company has a fifty day moving average price of $597.53 and a 200 day moving average price of $609.74. The stock has a market cap of $38.44 billion, a P/E ratio of -715.35 and a beta of 0.60.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. As a group, equities research analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

ARGX has been the subject of a number of recent research reports. Oppenheimer raised their price target on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Wedbush reaffirmed an “outperform” rating and set a $715.00 price objective on shares of argenx in a research report on Friday, April 11th. JMP Securities boosted their target price on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Citigroup raised their price target on shares of argenx from $681.00 to $796.00 and gave the company a “buy” rating in a report on Thursday, April 17th. Finally, Wells Fargo & Company upped their price objective on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.